This framework describes the building blocks being laid down by the European Centre for Disease Prevention and Control (ECDC) to support and empower European Union (EU)/European Economic Area (EEA) countries and the European Commission in achieving microbial safety for substances of human origin (SoHO).
On 5 and 6 September, ECDC hosted the first joint SoHO-Net Tissues and Cells (TC) and Medically Assisted Reproduction (MAR) group meeting in Stockholm, Sweden.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
Repository of resources produced by national public health institutes, national ministries of health, or recognised and respected learned societies or academies.
The purpose of this document is to address the safety of donors and products involving Substances of Human Origin (SoHO) and the potential risk of thrombosis with thrombocytopenia adverse events following COVID-19 vaccination of a donor.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
In order to assist Member States with the implementation of the new requirements, the EU Commission asked ECDC to construct a map indicating HTLV-1 high-prevalence areas in the world.